Letters to the Editor
Severe adrenal insufficiency complicating budesonide therapy for Crohn's disease
Charles Berkelhammer MD,
Mais Trabolsi MD,
Jelena Andrejic MD,
Tahira Yasmeen MD,
Charles Berkelhammer MD
Department of Gastroenterology, University of Illinois, Oak Lawn, Illinois
Search for more papers by this authorMais Trabolsi MD
Department of Gastroenterology, University of Illinois, Oak Lawn, Illinois
Search for more papers by this authorJelena Andrejic MD
Department of Gastroenterology, University of Illinois, Oak Lawn, Illinois
Search for more papers by this authorTahira Yasmeen MD
Department of Gastroenterology, University of Illinois, Oak Lawn, Illinois
Search for more papers by this authorCharles Berkelhammer MD,
Mais Trabolsi MD,
Jelena Andrejic MD,
Tahira Yasmeen MD,
Charles Berkelhammer MD
Department of Gastroenterology, University of Illinois, Oak Lawn, Illinois
Search for more papers by this authorMais Trabolsi MD
Department of Gastroenterology, University of Illinois, Oak Lawn, Illinois
Search for more papers by this authorJelena Andrejic MD
Department of Gastroenterology, University of Illinois, Oak Lawn, Illinois
Search for more papers by this authorTahira Yasmeen MD
Department of Gastroenterology, University of Illinois, Oak Lawn, Illinois
Search for more papers by this authorNo abstract is available for this article.
REFERENCES
- 1 Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med. 1994; 331: 836–841.
- 2 Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Gastroenterology. 1996; 110: 45–51.
- 3 Löfberg R, Rutgeerts P, Malchow H, et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. Gut. 1996; 39: 82–86.
- 4 Hanauer S, Sandborn WJ, Persson A, et al. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. Aliment Pharmacol Ther. 2005; 21: 363–371.
- 5 Hellers G, Cortot A, Jewell D, et al. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. Gastroenterology. 1999; 116: 294–300.
- 6 Benchimol EI, Seow CH, Otley AR, et al. Budesonide for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009; 1: 51–52.
- 7 Lichtenstein GR, Bengtsson B, Hapten-White L, et al. Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis. Aliment Pharmacol Ther. 2009; 29: 643–653.
- 8 Beaulieu DB, Ananthakrishnan AN, Issa M, et al. Budesonide induction and maintenance therapy for Crohn's disease during pregnancy. Inflamm Bowel Dis. 2009; 15: 25–28.
- 9 Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med. 1999; 159: 941–955.
- 10 Molimard M, Girodet PO, Pollet C, et al. Inhaled corticosteroids and adrenal insufficiency: prevalence and clinical presentation. Drug Saf. 2008; 31: 769–774.
